Twitter Logo Youtube Circle Icon LinkedIn Icon

The Legal 500 Hall of Fame Icon The Legal 500 Hall of Fame highlights individuals who have received constant praise by their clients for continued excellence. The Hall of Fame highlights, to clients, the law firm partners who are at the pinnacle of the profession. In Europe, Middle East and Africa, the criteria for entry is to have been recognised by The Legal 500 as one of the elite leading lawyers for seven consecutive years. These partners are highlighted below and throughout the editorial.
Click here for more details

France > Industry focus > Healthcare and life sciences > Law firm and leading lawyer rankings


Index of tables

  1. Industry focus: Healthcare and life sciences
  2. Hall of Fame
  3. Leading individuals
  4. Next generation lawyers

Hall of Fame

  1. 1

Leading individuals

  1. 1

Next generation lawyers

  1. 1
    • Stéphanie de Giovanni - CMS
    • Eveline van Keymeulen - Allen & Overy LLP
    • Sophie Pelé - Dechert LLP

Who Represents Who

Find out which law firms are representing which Healthcare and life sciences clients in France using The Legal 500's new comprehensive database of law firm/client relationships. Instantly search over 925,000 relationships, including over 83,000 Fortune 500, 46,000 FTSE350 and 13,000 DAX 30 relationships globally. Access is free for in-house lawyers, and by subscription for law firms. For more information, contact


Allen & Overy LLP’s ‘top tier’ multidisciplinary team is ‘responsive, extremely knowledgeable about the healthcare industry, the client’s needs and the relevant technology’ and ‘provides thoughtful and appropriate advice’. Clients especially note practice co-head and expert patent litigator Laëtitia Bénard and counsel Eveline Van Keymeulen who focuses her practice on EU life sciences regulatory advice. The team is currently representing Merck’s subsidiaries in a patent litigation filed by several parties pertaining to a drug used for the treatment of cancer, while practice co-head Alexandre Rudoni is advising a pharmaceutical company on regulatory issues arising from the de-certification of its medical devices in the EU. On the corporate side, Rudoni collaborated with the M&A practice to assist Bayer Santé Familiale with the sale of its consumer business to SBM Développement, and the group also advised a pharmaceutical company on regulatory issues arising from the setting up of its business in France. Other notable clients include GlaxoSmithKline, Pfizer and Novartis.

Dechert LLP’s healthcare and life sciences offering consists of a multidisciplinary team led by corporate specialist Alain Decombe. Sophie Pelé recently made partner in the regulatory practice and worked alongside competition expert Mélanie Thill-Tayara to advise Roche on the ‘off-label’ use of its drug Avastin. In other work, Decombe acted for Ipsen in its cross-border acquisition of Merrimack Pharmaceuticals’ global oncology assets, Anne-Charlotte Rivière assisted French health insurance plans start-up Alan with its seed fundraising and insurance license, and Jacques Sivignon, who heads the firm’s litigation department in France, handled a number of disputes for a major global pharmaceutical company. The impressive client roster also includes Allergan and Johnson & Johnson. Marianne Schaffner joined Dentons in 2018.

Dentons provides advice ‘of the highest quality’ to clients in the healthcare and life sciences sectors. Practice co-head Jean-Marc Grosperrin and senior of counsel François Vignaud recently advised Pfizer on the sale of its global infusion therapy business to ICU Medical and Servier instructed the group to handle its acquisition of a stake in Swiss biotechnology company GeNeuro as part of the two companies’ strategic international partnership. In other noteworthy work, Julien Le Guyader advised Bioxis on its distribution agreements with a Chinese clinic as well as on the sale of 18% of its stake to Juvamed. Other key clients include Allergan, Bristol-Myers Squibb and Actavis. Anne-Laure Marcerou impresses with ‘her expertise in the sector and her pragmatic, methodical approach’, practice co-head Pascale Poupelin is ‘a rare specialist in both public and private law’ as well as a ‘great agent for thorny negotiations in the pharmaceutical space’ and Olivia Guéguen is another name to note. Marianne Schaffner was a new arrival from Dechert LLP in 2018.

Hogan Lovells (Paris) LLP’s multidisciplinary team is headed by Cécile Derycke and advises on the whole array of contractual, corporate, intellectual property, competition and real estate issues. The group is leading the global defence of a provider of certification services in product liability proceedings arising from the allegedly inappropriate certification of French breast implant manufacturer PIP, and Stanislas Roux-Vaillard is acting for Lilly in a generic attack on its oncology product Alimta. On the corporate front, Dominique Mendy advised Merck on the termination of its vaccine joint venture with Sanofi, and Mikael Salmela was instructed by a global neurovascular company to oversee the reorganisation of its distribution business in Europe after its acquisition of a privately held company. Winston Maxwell, Eric Paroche and counsel Patrice Navarro are other names to note.

McDermott Will & Emery AARPI’s healthcare and life sciences department frequently represents big pharmaceutical and biotechnology clients: Servier recently appointed the team to advise on its research agreement with Transgene, and practice head Emmanuelle Trombe advised Innate Pharma on its acquisition of the Anti-C5aR antibody from Novo Nordisk. Other notable work highlights included assisting ImCheck Therapeutics with a financing matter, acting for a foreign fund in its investment in a retail pharmacy chain, as well as providing several clients with regulatory advice pertaining to clinical studies and licensing agreements for research and development projects. The group recently welcomed data privacy and protection expert Romain Perray from ANDCO Avocats; transactional specialist Anthony Paronneau and associate Anne-France Moreau are other names to note.

The healthcare team at Reed Smith consists of eight partners and acts for biotechnology, pharmaceutical and start-up companies in issues pertaining to intellectual property, product liability, regulations and distribution law. Corporate partner Isabelle MacElhone, competition partner Marc Lévy, who recently joined the firm with Natasha Tardif following the closure of King & Wood Mallesons’ Paris office, Marie Albertini and Daniel Kadar are key names. Intellectual property partner Marina Cousté is also active in healthcare matters.

Alain Gorny and Diane Bandon-Tourret head the healthcare and life sciences department at Sea Avocats and collaborate closely with Hervé Gabadou’s e-health and IT team. Among the team’s varied caseload are several product liability actions, a large-scale class action suit, regulatory advice on internal laboratory policies and financial participation by private establishments in publically led healthcare projects, as well as the defence of a medical products manufacturer in criminal proceedings. Also notable is the group’s work with regards to market access and negotiations with national authorities.

Simmons & Simmons LLP’s ‘very technical and pragmatic’ team ‘has in-depth knowledge of the sector, genuinely cares for its clients’ and provides ‘practical and business-oriented legal opinions’. In recent notable corporate work, Christian Taylor and Simonetta Giordano advised Wright Medical and Tornier SAS on the sale of their hip and knee implants business to Corin Orthopaedics, and assisted Balt International with its acquisition of two companies constituting a medical device distributor in Germany. Competition expert Ombline Ancelin is currently representing Centrale des Opticiens in three separate proceedings against a healthcare network of opticians pertaining to alleged violations of competition and commercial law as well as a private damages claim. Clients also instructed the group to handle liability litigation, tax issues arising from promotional activities, and software implementation work. Tax partner Jean-Luc Cuadrado and Jacques-Antoine Robert are also recommended by clients. Alexandre Regniault heads the team. Guillaume-Denis Faure was a new arrival in 2018 from Winston & Strawn LLP.

August Debouzy combines the expertise of its intellectual property, corporate, competition, litigation, employment and regulatory practices to service clients in the generics, medical device and cosmetics industries. On the contentious front, Alexandra Cohen-Jonathan is representing Lima in a damages claim brought by several hip prosthesis users, and François Pochart successfully represented Teva in a series of patent infringement claims against Warner Lambert and two Pfizer subsidiaries. Florence Chafiol assisted with the data privacy and protection issues of a new medical device that is also subject to an e-health application in France, and Julien Wagmann advised start-up Glowee on its venture capital funding. Regulatory expert Vincent Brenot and employment partner Virginie Devos are other names to note.

Bird & Bird has ‘a highly skilled team to handle patent litigation in the pharmaceutical field’ and its ‘very creative, business and client-oriented’ lawyers ‘always provide an excellent service’. On the corporate side, Emmanuel Porte recently joined the firm from Redlink and advised on a number of partnerships and fundraising matters for the development of novel therapeutic methodologies. In notable contentious work, Annet van Hooft successfully represented a major pharmaceutical company in ICC arbitration proceedings arising from the licensing for the commercial production of a blockbuster drug. Additionally, Ariane Mole frequently advises on data protection regulations and the new obligations attached to the GDPR. Yves Bizollon ‘always gives sound and practical advice in a timely fashion’ and jointly heads the patent litigation team with Anne-Charlotte le Bihan; commercial partner Alexandre Vuchot is also recommended.

The ‘always perfect’ healthcare and life sciences offering at CMS advises on competition, contractual, intellectual property and corporate law issues with ‘astounding pertinence and an outstanding understanding of the problems clients may encounter’. Pharmaceutical regulatory expert Bernard Geneste successfully represented a French company specialised in orthopaedic implants in appeal proceedings against a decision by the French Economic Committee for Medicinal Devices regarding a price decrease for some devices, and Anne-Laure Villedieu advised a foreign medical device manufacturer on IP agreements with a research institution and a laboratory. Counsel Stéphanie de Giovanni is known for her ‘responsiveness and accurate advice’ and assisted a client with the setting up of a clinical trial. The group also has significant capacities in data privacy and protection work. Laurent Romano is the name to note in the Lyon office.

De Gaulle Fleurance & Associés’ team advises healthcare and life sciences clients on a vast array of issues in the fields of competition, intellectual property, insurance and commercial law. Cécile Théard-Jallu and Jean-Marie Job recently assisted DietSensor with the parallel launch of a new connected nutrition scanning device in France and the US, and Blandine Fauran collaborated with intellectual property partner Francine Le Péchon-Joubert to assist a pharmaceutical laboratory with allegedly unlawful and misleading advertising in the context of a convention. Other notable work included assisting a pharmaceutical company with a claim for the misappropriation of data files and libel related to the change of regional distributor. Senior manager Lionel Attal has extensive experience in commercial contracts and is a notable contact alongside public law partner Frédéric Destal.

Regulatory expert Olivier Lantrès heads Fieldfisher’s multidisciplinary healthcare and life sciences department: in recent highlights, head of the corporate team Philippe Netto collaborated with Lantrès to advise Dômes Pharma on its acquisition of a foreign company, and Brigitte Daille-Duclos handled a series of product liability claims pertaining to allegedly defective medical devices. Counsel Sébastien Pradeau and associate Caroline Savoie were part of the team which obtained the suspension of an injunction against a pharmaceutical company following an inspection by the French Drug Agency; and other work included assisting an international client with the drafting, negotiation and signing of contracts pertaining to a Europe-wide clinical trial. Anne-Laure-Hélène des Ylouses heads the competition and EU law department and distribution contracts specialist Franck Veisse is another name to note.

Gide Loyrette Nouel A.A.R.P.I.’s healthcare and life sciences group has strong intellectual property, corporate and competition law expertise and is led by Grégoire Triet, Anne Tolila and Dimitri Dimitrov, respectively. Jean-Hyacinthe de Mitry advised biopharmaceutical company Annapurna Therapeutics on its merger with Avalanche Biotechnologies, and Raphaëlle Dequiré-Portier teamed up with Emmanuel Larere to represent Ono and Bristol-Myers Squibb in a multijurisdictional patent litigation pertaining to an innovative cancer treatment. In other recent highlight work, Arnaud Michel represented Merck and five of its subsidiaries in trade mark infringement and unfair competition proceedings regarding the use of the name ‘Merck’ in France, and Dimitrov assisted a manufacturer of medical devices with the review of its contracts in light of French distribution law provisions. Other notable clients include Johnson & Johnson, Shionogi and Guerbet.

HBC Avocats specialises in corporate governance and contractual work for clients in the healthcare and life sciences sector. In recent highlights, the group advised biotechnology company OSE Immunotherapeutics on a global licensing and partnership agreement with Servier for the development and commercialisation of the Effi-7 antibody, and assisted AFM-Téléthon with intellectual property and licensing aspects of its creation of YposKesi, a French company dedicated to the production of genetic and cellular treatments for rare diseases. The firm’s client roster also includes names such as Valneva, Xoma and Cytoo. Founding partner Jonathan Burnham is the key contact.

Jones Day’s healthcare and life sciences offering is globally led by environment and health and safety expert Françoise Labrousse, while the cross-departmental team in France is headed by corporate and private equity partner Renaud Bonnet; further strengthening its comprehensive service offering, the group recently welcomed patents expert Thomas Bouvet from Véron & Associés . In recent highlights, the corporate group advised Nanbiotix on two private placements in Europe and the US, while the environment unit defended a global corporation in criminal proceedings related to two legionella outbreaks. Emmanuel Baud heads the intellectual property team and recently assisted Merck with French aspects of a multijurisdictional patent litigation regarding its blockbuster drug Solvadi. Other key clients include Sanofi, Novartis and Abbott.

Viguié Schmidt & Associés is the result of the recent merger between Viguié Schmidt and SLVF and its healthcare offering focuses on regulatory issues, commercial disputes, competition law and product liability claims. Practice heads Etienne Gouesse and Iñaki Saint Esteben recently assisted Sanofi with a series of liability actions brought by patients suffering neurological diseases which were allegedly caused by the client’s hepatitis vaccine as well as with a commercial dispute brought by an Israeli distributor seeking compensation following the termination of its contract. Other work highlights included defending Lilly in proceedings brought by an egg hatchery company pertaining to the alleged contamination of the client’s chicken feed, and defending Abbott in a product liability compensation claim. Other notable clients include Johnson & Johnson, Shire and Abbvie.

Winston & Strawn LLP’s team of four partners covers all legal aspects pertaining to the healthcare and life sciences space including financing, joint venture agreements, real estate and contentious matters, among others. Recent work includes assisting Azimut with the sale of a controlled stake in natural health products manufacturer Ponroy Santé to a private equity fund. Managing partner Gilles Bigot and Mathilde Lefranc-Barthe are advising Laboratoire ZTP on the creation of a centre for medically-assisted procreation. In other work, Anne-Carine Ropars-Furet recently teamed up with Bigot to handle a wrongful dismissal dispute on behalf of a former director and shareholder of a medical laboratory in Paris, and counsel Julie Vern Cesano-Gouffrant recently assisted a player in the medical biology sector with the negotiation of a partnership agreement. Biopath, Vivalto and the Red Cross are also notable clients. Guillaume-Denis Faure joined Simmons & Simmons LLP in 2018.

Adamas ‘is equipped with strong technical, regulatory and contractual expertise in the field of healthcare, pharmaceutical law and medical devices’, and clients also value its ‘integrated offer embodied in its vast network of specialists’. Practice head Barbara Bertholet, whose ‘double competence in healthcare and intellectual property makes her the perfect spearhead for medical devices matters’, represented a German medical device manufacturer before the French commercial court regarding the former distribution of its products to French hospitals, and a multinational pharmaceutical company instructed her team to advise on a criminal investigation pertaining to competition and regulatory issues. Jean-Baptiste Chanial handles licensing and regulatory issues as well as personal data protection work for pharmaceutical clients.

The healthcare lawyers at Altana ‘are very professional and effective’ and led by litigation specialist Armand Aviges who intervenes in product liability and class action suits on behalf of major French and international pharmaceutical industrial clients. Other noteworthy work highlights included defending a major pharmaceutical company in a product liability class action and against numerous individual claims, and Frank Valentin defended a European pharmaceutical company in a patent infringement suit brought by a global competitor. Jean-Nicolas Soret specialises in M&A and joint ventures and is also a key contact. Arnaud Fayolle departed the firm to take up a deputy chief executive officer position with a former client.

Baker McKenzie’s fully-dedicated healthcare team is headed by Julie Yeni and receives regular support from the firm’s corporate department and data privacy practice. In recent highlight work, the group assisted ICU Medical with its acquisition of Pfizer’s Hospira infusion system business, and advised a global leading medical technology company on regulatory repercussions of the phasing out of direct sponsorship of healthcare professionals. The practice’s recent caseload also includes advising a multinational pharmaceutical company on negotiations with third party distributors, and a series of product liability claims pertaining to allegedly defective vaccines. AbbVie, Abbott and Medtronic are other notable clients.

Clifford Chance is known for its ‘excellent service, fast and efficient responses, broad expertise in life sciences and detailed knowledge of the industry’. Counsel Marion Roquette-Pfister advised Pfizer on its market access strategy and price negotiations with the French authorities and also collaborated with the corporate team to advise Cinven on its acquisition of Labco from a consortium of investors. On the regulatory side, ‘very knowledgeable and always available’ counsel Olivier Gaillard advised Insmed on compliance issues regarding new transparency and anti-gift rules, and Thomas Baudesson handled a number of disputes arising from alleged defects in vaccines and other medicinal products as well as commercial litigation proceedings pertaining to the termination of distribution agreements. Litigation expert Marguerite Aynès was recently promoted to counsel.

Sonia de Kondserovsky and Jean-Christophe Tristant lead DLA Piper’s healthcare department which recently attracted a number of new high-profile clients such as Becton Dickinson, Servier and Pierre Fabre. 2017 highlights included advising Lion Biotechnologies on regulatory and data privacy issues related to the conduct of clinical trials in Europe as well as handling a series of disputes including a patent infringement and unfair competition claim on behalf of a client in the skincare field. The group also assisted a pharmaceutical company with several product supply agreements and with a worldwide corporate restructuring covering over 36 jurisdictions. Associate Marie-Charlotte Mevel plays a key supportive role in the team and is also a key contact.

Known for its ‘business acumen and availability’, Ginestié Magellan Paley-Vincent’s healthcare practice focuses on corporate governance and contractual advice to private and public institutions, medical laboratories and individual practitioners. Catherine Paley-Vincent heads the team and recently defended a number of doctors in civil and criminal medical liability cases, advised companies and individuals on compliance with ethical regulations, and assisted a biological laboratory with the launch of a new veterinary product. Clients also instructed the group to oversee the setting up and management of governance structures, namely in connection with telemedicine and connected health projects in the context of genetic tests.

Hoyng Rokh Monegier’s ‘extremely strong’ team has deep expertise in advising major pharmaceutical and biotechnology companies on contentious patent issues and pharmaceutical regulatory matters. Led by ‘unflappable and very experienced’ Brussels-based patent law expert Benoît Strowel and regulatory specialist Anne Servoir, who recently joined from pharmaceutical law boutique firm Intuity, the practice is representing Zeltiq Aesthetics in several patent litigation proceedings pertaining to Cryolipolisys, a treatment process designed to eliminate fat cells through cooling. On the regulatory front, clients instructed the firm to advise on market access strategy, negotiations with national authorities, and tax issues relating to marketing and advertising activities by pharmaceutical players in France. Other noteworthy clients include Sanofi, Ferring Pharmaceuticals, Lundbeck and Audevard Laboratories.

Christophe Hénin is the name to note at healthcare and life sciences boutique Intuity: he advises pharmaceutical companies, laboratories and medical device start-ups on a vast array of issues. The team’s main strengths lie in regulatory advice, competition law and litigation pertaining to product liability.

Headed by Jean-Patrice Labautière, K&L Gates LLP’s team has particular strength in the M&A and private equity spaces. Assisting Sanofi with the termination of a joint venture with Merck in Europe, and advising US medical technology company Axonics on its €35m fundraising are a few of the team’s recent successes. Also noteworthy is corporate partner Nicola Di Giovanni who recently advised on the sale of severeal retirement homes. Other key clients include Ardian, Riverside and Remedica.

Lmt Avocats provides regulatory and litigation advice to major healthcare clients. In recent contentious highlights, the group represented Boehringer Ingleheim in an unfair competition claim against Novartis with regards to one of the defendant’s veterinary products, and acted for clients in a number of advertising issues including false claims and regulatory breaches. Notable counsel work includes transactional mandates, the opening of healthcare establishments in foreign jurisdictions, and the negotiation of patent licensing contracts. The names to note are Antoine Lemétais and Olivier Samnyn.

Norton Rose Fulbright’s ‘excellent’ team was kept busy in 2017: the recommended Marta Giner Asins recently advised Pfizer on competition and antitrust issues with regard to its commercial structure and, on the corporate side, Stephane Sabatier is acting for a major German biopharmaceutical group in the contemplated merger of two of its subsidiaries as part of its efforts to reorganise its French operations. The team also continues to handle intellectual property and tax aspects of Roche’s acquisition of Marseille-based biotechnical company Trophos. Of counsel Arnaud Sanz is also a key contact.

Pech de Laclause Bathmanabane & Associés was recently particularly active in assisting start-ups, laboratories and pharmaceutical companies with regulatory issues pertaining to data protection and e-health projects. Also notable is the team’s advice to several pharmaceutical laboratories regarding the transparency obligations of the new ‘anti-gift’ legislation, and Michèle Anahory’s work for a biotech company with regards to market access issues and the launch of a new product; Anahory has lonstanding experience in advising on price fixing matters and partnership contracts in the context of research projects, as well as in representing manufacturers in regulatory inspections.

The core of Squire Patton Boggs’ healthcare and life sciences practice is liability litigation on behalf of medical device manufacturers and pharmaceutical companies, including criminal investigations and proceedings as well as class actions. Practice co-head Valérie Ravit is representing Huntsman in a multijurisdictional product liability litigation pertaining to the coating of food supplements and drugs, and practice co-head Carole Sportes defended Siemens in a large-scale action before the French Court relating to cases of Lyme disease. Other work included representing AIG in several medical malpractice disputes against an entity formerly insured by AIG.

Interview with...

Law firm partners and practice heads explain how their firms are adapting to clients' changing needs

International Law Firm Networks

Press releases

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to

Legal Developments in France

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to

    The People's Republic of China has initiated an overhaul of its social security system, reformed the personal taxation regime and has extended the scope of these laws to foreigners residing in China.

    The Kingdom of Morocco is supporting the ambition of becoming the leading financial place for Africa. In this context, a wave of draft laws is to be passed and implemented within the following months, amongst which, the Law No. 53.08, setting up a new financial authority, and the Law No. 54.08, reforming public offering rules, are of paramount importance to Moroccan and foreign issuers, and financial institutions.

    The opportunities offered to foreign investors by the Chinese mergers and acquisitions market are increasing every year: in 2010, transactions involving foreign companies came to 60.1 billion euros, an increase of 21.2% compared with 2009. Seen from the West, where markets are declining, all sectors of the Chinese economy seem to be undergoing promising development and the statistics indicate that the Middle Empire will be a lasting springboard for growth.
  • Prime de Partage des Profits

    Le dispositif L’article 1er de la loi de financement rectificative de la Sécurité sociale pour 2011 oblige les sociétés commerciales de 50 salariés et plus, dont les dividendes par part sociale ou par action sont en augmentation par rapport à la moyenne des deux années précédentes, à verser une prime à l’ensemble de leurs salariés

    Types of investors The private equity (PE) funds that are active in Bulgaria are not raised or registered in the country. Some Bulgarian PE funds were raised recently, but there are no statistics as to the sources of their funding, their number, the funds that were accumulated, etc.

  • Landmark decision by French Competition Authority in conditioned LPG case

    cartel case closed after discovery that leniency application was largely based on forgeries and rejection of collective dominant position objection.
  • 2012 supplementary budget

    The second supplementary budget published in the Official Gazette September 19, 2011 provides for two key measures that affect the deferral of tax losses and taxation of capital gains realized on the sale of equity securities .
  • Actualité législative fiscale

    Au delà des mesures applicables à l’ensemble des contribuables (telles que la limitation du report des déficits ou la réforme du mode de calcul des plus values sur cessions de participations),le plan de réduction des déficits annoncé le 24 août dernier par le gouvernement comprend des mesures qui intéressent spécifiquement les acteurs du secteur financier.
  • Réforme fiscale

    À la une Parmi les mesures annoncées par le Premier Ministre dans le cadre du plan de réduction des déficits, deux d’entre elles sont susceptibles d’affecter de nombreuses entreprises

Press Releases worldwide

The latest news direct from law firms. If you would like to submit press releases for your firm, send an email request to